# uniQure N.V.

Type: Company (QURE)

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/uniqure-nv
Canonical HTML page: https://getbiobrief.com/entity/uniqure-nv

## Timeline

- **2026-Q3**: Anticipated Amended Complaint — Expected filing of detailed allegations following the appointment of lead plaintiffs.
- **2026-06-12**: SEC filings and market close — Stock closes at $27.57, up 2.8%; SEC Form 4 filings reveal the three insider transactions.
- **2026-06-11**: Insider sales executed — Directors Kaye, Balachandran, and Meek each sell 1,993 shares at $27.06.
- **2026-05-05**: Q1 2026 earnings — uniQure reports revenue of $3.56M (miss) and EPS of -$0.85 (beat by $0.03); net margin remains deeply negative.
- **2026-04-13**: Lead Plaintiff Deadline — Final date for eligible investors to file applications in the class action lawsuits against QURE and KD.
- **2026-03-09**: RBC upgrade — RBC Capital upgrades uniQure from sector perform to outperform, raising price target from $11 to $35.
- **2026-02-18**: Legal Alert Issued — ClaimsFiler reminds shareholders of upcoming deadlines for lead plaintiff applications.

## Recent coverage (2 stories)

### 3 uniQure Directors Each Sell 1,993 Shares; Stock Now $27.57
2026-08-05 19:24:48 · Sentiment: Neutral · Impact: 5/10 · Sources: 3

Three uniQure directors each offloaded 1,993 shares at $27.06, pocketing a combined $162K. The gene therapy company’s stock trades above key moving averages after an RBC upgrade, but sales hint at insider caution amid heavy cash burn.
Full story: https://getbiobrief.com/story/uniqure-insider-sales-3-directors-sell-1993-shares-27-57

### uniQure and Kyndryl Face April Deadlines in Securities Class Action Lawsuits
2026-02-19 19:43:15 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Investors in uniQure N.V. and Kyndryl Holdings have until April 13, 2026, to file as lead plaintiffs in securities class action lawsuits following significant stock losses. The litigation highlights increasing regulatory and disclosure pressures on biotech firms specializing in complex gene therapies.
Full story: https://getbiobrief.com/story/uniqure-kyndryl-securities-class-action-deadlines

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.